Clinical Trials on Molecular Pathway Deregulation in Hong Kong
Total 8 results
-
City University of Hong KongInternational Social Service Hong Kong BranchRecruitingParent-Child Relations | Happiness | Emotion Regulation | Positive AffectChina
-
The University of Hong KongThe Hong Kong Polytechnic University; The University of Queensland; Health and...RecruitingAnxiety | Depressive Symptoms | Loneliness | Emotion RegulationHong Kong
-
The University of Hong KongCompletedADHD | Emotion Regulation | Parenting InterventionHong Kong
-
Novartis PharmaceuticalsTerminatedAdvanced Hepatocellular Carcinoma With c-MET DysregulationChina, Hong Kong, Thailand, Singapore
-
Novartis PharmaceuticalsCompletedPre-menopausal Breast Cancer | PI3K Pathway InhibitionTaiwan, Hong Kong, Thailand, Korea, Republic of
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
National Cancer Institute (NCI)CompletedNeurofibromatosis Type 1 | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Childhood Visual Pathway GliomaUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Ependymoma | Childhood Craniopharyngioma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland